Why Was Vir Biotechnology Up 74% in February? [The Motley Fool]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: The Motley Fool
What happened Shares of Vir Biotechnology ( NASDAQ:VIR Global Market Intelligence 00 Why the dominant outperformance? Vir is one of a handful shot up Of course it's way too early for trial data, and it will likely be years before any drug is approved by the Food and Drug Administration (FDA). Nonetheless, in a COVID-9 meltdown, small-cap stocks Image source: Getty Images. So what Vir's market cap is $. billion dollars now. That is very expensive for a company that has no profits, and only had $0 million in revenue last year. Vir's most advanced molecule is its hepatitis B treatment, Vir-8, in phase trials. If it works, Vir-8 will be a billion-dollar molecule for sure. So for long-term investors, progress on its hepatitis B drug is far and away the most important thing about this biotech. Driving the incredible gains in the share price in the short term, of course, is its COVID-9 program. And it's not like the market is bullish about good news from a clinical trial. The company has
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.MarketBeat
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.MarketBeat
- Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramBusiness Wire
- Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 10/31/24 - Miss
VIR
Sec Filings
- 11/18/24 - Form 4
- 11/7/24 - Form 4
- 11/6/24 - Form 144
- VIR's page on the SEC website